Region — International. Neutral scientific reference — not offered for sale here.

Set region

Explore Shop Tools Journal Trust

Explore  /  Petrelintide

Research reference — not for sale

Petrelintide

B

lead outcome

Weight loss / obesity

grades vary by outcome ↓

Peptide

also called — Petrelintide · ZP8396 (Zealand development code) · a long-acting amylin analog

weight management / obesityamylin-receptor agonism (satiety / leptin resensitization)combination-ready (non-incretin partner)

The "gentle weight loss" amylin — where placebo-like tolerability met a disappointed market. Petrelintide is one of the freshest, most instructive entries in the register: a next-generation amylin analog (Zealand/Roche) whose 2026 Phase 2 delivered a genuinely remarkable tolerability result — and whose stock still fell 30% because the weight loss underwhelmed a GLP-1-spoiled market. Three threads: (1) it's the modern realization of the amylin idea that Pramlintide (#54) pioneered — once-weekly, meaningful weight loss; (2) its headline is "placebo-like tolerability" — fewer GI side effects than placebo in the best arm; (3) it's a live lesson in the post-GLP-1 market: in obesity today, efficacy magnitude still rules, and "gentler" isn't automatically enough. Advancing to Phase 3.

In brief

Petrelintide is a long-acting, once-weekly amylin analog (Zealand Pharma, partnered with Roche in a $5.3 billion deal) — the modern realization of the amylin approach that Pramlintide (#54) pioneered decades ago. Amylin normally rides shotgun with insulin to signal fullness; petrelintide's analog restores sensitivity to the satiety hormone leptin, helping people feel full sooner — a non-incretin mechanism distinct from GLP-1 drugs. Its 2026 Phase 2 (ZUPREME-1) hit its primary endpoint with up to 10.7% weight loss at 42 weeks, but the standout was tolerability: discontinuations matched placebo (4.8% vs 4.9%), and vomiting was actually less frequent than placebo — a striking contrast to the GI burden of incretin drugs. Yet in a hypercompetitive post-GLP-1 market, the ~10.7% figure looked modest next to Wegovy/Zepbound, and Zealand's stock fell over 30% despite the trial win — a vivid lesson that efficacy magnitude still dominates obesity, and "gentler" alone isn't enough. Designed to be combination-ready (no fibrillation at neutral pH), petrelintide is heading to Phase 3 as both a monotherapy and a partner for Roche's GLP-1/GIP dual. For the register it's the "tolerability-play" pole of the amylin class and a real-time case study in how the obesity market now judges new entrants.

Legal standing, by region

European Union

Not FDA-approved (gray-market)

investigational; not approved. In Phase 2 completed → Phase 3 planned (H2 2026); a genuine, well-capitalized big-pharma clinical program (Roche/Zealand), not a gray-market compound.

Evidence, by outcome

How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade

Weight loss / obesity

Solid Phase 2 signal — but not yet Phase 3-confirmed, and the magnitude lags incretin leaders (the market's disappointment); women responded more than men

Phase 2 ZUPREME-1 (493 pts): met primary endpoint; up to 10.7% at 42 wk vs 1.7% placebo; Phase 1b MAD ~5.3% over 6 wk

B

Tolerability (the differentiator)

The genuinely standout result — placebo-like tolerability, a real potential adherence/combination advantage

Phase 2: discontinuation 4.8% vs 4.9% placebo; vomiting < placebo; no vomiting in best arm; 98% reached maintenance dose

A

Combination therapy (with CT-388)

Rationale strong (amylin + incretin complementary); no combination efficacy data yet

Designed combination-ready; Phase 2 combo planned H2 2026

—

Type 2 diabetes (ZUPREME-2)

Data pending

Trial ongoing; readout later

—

Lean-mass preservation

Plausible/claimed; not yet robustly demonstrated for petrelintide specifically

Hypothesized class advantage of amylins

C

Safety

No unexpected safety signals; mostly mild GI AEs; investigational — long-term/Phase 3 safety still to come

Phase 2 (493) + Phase 1b

B

Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for Petrelintide changes - nothing else.

Identity

a synthetic, long-acting analog of amylin — the hormone co-secreted with insulin by pancreatic beta cells after eating — engineered for once-weekly subcutaneous dosing. A defining design feature: it's chemically and physically stable with no fibrillation around neutral pH, which (unlike native amylin) lets it be co-formulated and co-administered with other peptides — a deliberate "combination-ready" design. Developed by Zealand Pharma, partnered with Roche (2025).

Mechanism (as proposed)

amylin is a hormone co-secreted with insulin by pancreatic beta cells in response to food. Acting at amylin receptors (in the hindbrain/area postrema), it promotes satiety — and, importantly, it restores sensitivity to leptin, the fat-derived "fullness" hormone that obesity tends to blunt (leptin resistance). Petrelintide is a long-acting amylin analog that sustains this signalling with once-weekly dosing, so people feel full faster and eat less. Because this is a different pathway from GLP-1/GIP incretins, amylins are seen as complementary — hence the combination strategy (petrelintide + CT-388). The engineering achievement is stability without fibrillation at neutral pH (native amylin is amyloidogenic — the same problem that shaped Pramlintide's design), which both enables weekly dosing and makes petrelintide co-formulable with other peptides.

Chemical identifiers

Cross-reference identifiers for the authoritative external databases — not a recipe, and nothing about how to use it.

CAS2766385-23-1

PubChem CID172915807

InChIKeyTVOIUFVYEVVHCS-HJODGROVSA-N

SMILESCC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1C[C@H](C[C@H]1C(=O)N)O)N(C)C(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H]4CCCCNC(=O)C[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)[C@@H](C)O)C)[C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O

via PubChem exact-name match (Petrelintide) · high confidence

Sources — 4 cited

01Roche press release (5 March 2026): positive Phase II ZUPREME-1 topline — up to 10.7% weight loss at 42 wk vs 1.7% placebo; discontinuation 4.8% vs 4.9%; vomiting < placebo.

02Zealand Pharma pipeline / press (29 April 2026): advancing to Phase 3 (H2 2026); Phase 1b MAD ~5.3% over 6 wk; no-fibrillation/combination-ready design; leptin-resensitization mechanism (Roth et al. PNAS 2008; Mathiesen et al. Eur J Endocrinol 2022).

03Roche–Zealand collaboration (March 2025): up to $5.3B, $1.65B upfront; CT-388 combination.

04FierceBiotech (6 March 2026): "placebo-like tolerability"; Zealand stock −30%; William Blair downgrade on "disappointing" weight-loss magnitude. ClinicalTrials.gov NCT06662539. (Investigational; not approved as of 2026.)

Updated 2026-07-13 (fast-moving: Phase 3 start H2 2026, ZUPREME-2 diabetes readout, and the CT-388 combination Phase 2 are the catalysts to watch)

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds

Pramlintide (Symlin)A

Explore by goal

A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.

Region — International

ExploreRegister The Register — full index Categories Trust & COA How we grade Open data Brands

ShopCosmetic peptides Journal Quizzes

TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.